Stallion India Fluorochemicals Limited has announced that its Board of Directors will convene on January 29, 2026, to review and approve the company's third quarter financial performance for fiscal year 2026. The meeting represents a key milestone in the company's quarterly reporting cycle as it prepares to disclose its financial results to stakeholders.

Board Meeting Details

The scheduled board meeting will focus on considering, approving, and taking on record the unaudited financial results for both standalone and consolidated operations. The financial results will cover the quarter and nine months ended December 31, 2025, providing comprehensive insights into the company's performance during this period.

Regulatory Compliance

The announcement was made in strict adherence to Regulation 29 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company formally notified both major stock exchanges about the upcoming board meeting through official communications dated January 24, 2026.

Corporate Communication

The official intimation was signed by Govind Rao, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols were followed. The communication was digitally signed and timestamped, reflecting modern corporate practices and regulatory requirements. The company operates under its current name, having previously been known as Stallion India Fluorochemicals Private Limited before its transformation to a public limited company.

Stallion India Fluorochemicals Limited has announced its Board of Directors' approval for a significant rights issue worth up to ₹364.00 crores. The decision was taken during a board meeting held on Friday, January 23rd, 2026, at the company's registered office in Mumbai.

Rights Issue Structure and Details

The rights issue will comprise equity shares with a face value of ₹10.00 each, offered to eligible equity shareholders as on the record date. The board meeting, which commenced at 11:30 AM and concluded at 1:50 PM, approved the comprehensive framework for this capital raising initiative.

Rights Issue Committee Formation

The board has established a dedicated Rights Issue Committee comprising directors to oversee the entire process. This committee will have comprehensive authority to make crucial decisions regarding the rights issue implementation.

The committee's responsibilities include:

• Determination and alteration of fractional entitlements treatment
• Making necessary applications to regulatory authorities
• Finalizing terms, conditions, structure, and timing of the rights issue
• Overseeing the overall execution of the capital raising process

Key Parameters and Timeline

Several critical parameters remain to be finalized by the Rights Issue Committee and will be disclosed in the final Letter of Offer. These pending details include the specific issue price per equity share, exact number of equity shares to be offered, and the rights entitlement ratio for existing shareholders.

Regulatory Compliance and Next Steps

The announcement was made pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company will issue a detailed Letter of Offer to eligible equity shareholders holding shares as on the record date, which will specify comprehensive terms and conditions including the application procedure.

The rights issue represents a significant capital raising initiative for Stallion India Fluorochemicals, providing existing shareholders with the opportunity to participate in the company's growth plans through preferential share allocation based on their current holdings.